Young Investigator Award Interim Progress Report

  "Predicting Response to Antiangiogenic Therapies in Renal Cell Carcinoma" The ASCO Cancer Foundation has recently communicated with our researchers on the progress they have made during the first six months of their grant term. We are excited to share with you the update we received from Dr. Stephen Keefe, currently at work at the Hospital of the University of Pennsylvania through the generous support of the Kidney Cancer Association. Here is what Dr. Keefe had to say about his research: “The grant is being used to provide salary support for the principal investigator, Dr. Stephen Keefe, for time spent on a retrospective cohort study investigating single-nucleotide polymorphisms as molecular biomarkers of response to the treatment of patients with metastatic renal cell carcinoma with antiangiogenic therapy.  Thus, the relevant project is this cohort study.   Work on the study has proceeded well through the first half of the grant period.  The study cohort has been comprised from a group of patients with metastatic renal cell carcinoma treated on several phase II clinical trials with sorafenib.  Patients were treated with the drug through disease progression.  The phase II clinical trials have been completed.  Over the last 6 months, the clinical data pertaining to the care of these patients on study has been acquired.  Additionally, biological specimens have been collected, and DNA has been extracted from these spec...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news